IL-10 and CXCL2 in trigeminal ganglia in neuropathic pain

Neurosci Lett. 2019 Jun 11:703:132-138. doi: 10.1016/j.neulet.2019.03.031. Epub 2019 Mar 20.

Abstract

Many trigeminal neuropathic pain patients suffer severe chronic pain. The neuropathic pain might be related with cross-excitation of the neighboring neurons and satellite glial cells (SGCs) in the sensory ganglia and increasing the pain signals from the peripheral tissue to the central nervous system. We induced trigeminal neuropathic pain by infraorbital nerve constriction injury (IONC) in Sprague-Dawley rats. We tested cytokine (CXCL2 and IL-10) levels in trigeminal ganglia (TGs) after trigeminal neuropathic pain induction, and the effect of direct injection of the anti-CXCL2 and recombinant IL-10 into TG. We found that IONC induced pain behavior. Additionally, IONC induced satellite glial cell activation in TG and cytokine levels of TGs were changed after IONC. CXCL2 levels increased on day 1 of neuropathic pain induction and decreased gradually, with IL-10 levels showing the opposite trend. Recombinant IL-10 or anti-CXCL2 injection into TG decreased pain behavior. Our results show that IL-10 or anti-CXCL2 are therapy options for neuropathic pain.

Keywords: Chemokine; Cytokine; Glial cell; Neuropathic pain; Orofacial pain; Sensory ganglia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / pharmacology
  • Chemokine CXCL2 / immunology
  • Chemokine CXCL2 / metabolism*
  • Constriction, Pathologic
  • Interleukin-10 / metabolism*
  • Interleukin-10 / pharmacology
  • Male
  • Neuralgia / metabolism*
  • Neuralgia / physiopathology
  • Pain Measurement
  • Peripheral Nerve Injuries / physiopathology
  • Rats, Sprague-Dawley
  • Recombinant Proteins / pharmacology
  • Trigeminal Ganglion / metabolism*

Substances

  • Antibodies
  • Chemokine CXCL2
  • Cxcl2 protein, rat
  • IL10 protein, mouse
  • Recombinant Proteins
  • Interleukin-10